Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 2016

View Archived Issues

USP11 shows promise as a therapeutic target in breast cancer

Angle initiates European ovarian cancer study

Iron Horse Diagnostics and Euroimmun enter license agreement to launch first ALS biologic diagnostic

AstraZeneca receives European approval for Qtern

FDA grants orphan drug designation to combination of antibodies against Ebola

FORMA Therapeutics reports ubiquitin hydrolase inhibitors

Novira Therapeutics reveals antiviral compounds to treat hepatitis B

Merck KGaA initiates phase II trial in children with schistosomiasis

Eurpean Commission grants orphan drug designation to Alcobra's metadoxine

FDA advisory committee votes to recommend brodalumab for moderate to severe plaque psoriasis

Research identifies PARG as a potential target for breast cancer

Johnson & Johnson reflects on accomplishments of second quarter 2016

Synaffix platform technologies generate ADCs with improved therapeutic index

Genetic variation in a lincRNA gene is associated with pneumococcal bacteremia

Aeglea updates progress of AEB-1102 clinical program

Scientists discover novel ROMK inhibitor SHR-1977 for treating hypertension

Topline results from Arbutus' phase I/II study of TKM-PLK1 in HCC

Jounce Therapeutics and Celgene establish immuno-oncology collaboration

ProQR Therapeutics announces fast track designation from the FDA for QR-010

BladderPredict diagnostic tool launched for bladder cancer

Cynapsus Therapeutics reaches agreement with the EMA for APL-130277 development

FDA grants fast track designation to CRLX-101

Immune Pharmaceuticals enters agreement with NPT for AmiKet

Eisai and Arena Pharmaceuticals obtain NDA approval for Belviq XR

First-in-human trial begins for GLS-5700 vaccine against Zika virus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...